Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing whether a medicine called iberdomide can be given to people after a certain type of cancer treatment to see if it is safe and effective. The medicine will be taken once a day for 21 days out of each 28-day cycle, until either the cancer comes back or there are bad side effects. Up to 38 people will participate in the study to see if it is worth doing a bigger study later on.
This study is testing whether a medicine called iberdomide can be given to people after a certain type of cancer treatment to see if it is safe and effective. The medicine will be taken once a day for 21 days out of each 28-day cycle, until either the cancer comes back or there are bad side effects. Up to 38 people will participate in the study to see if it is worth doing a bigger study later on.
*Third Opinion AI Generated Synopsis
Trial Summary
This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.
This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: